What is Serapha Bio’s $230M launch and YolTech base-editing deal for AATD?

Serapha Bio debuted via a reverse merger with Boundless Bio, securing $230 million from investors led by RA Capital and RTW. Its lead therapy, SERP‑01, licensed from China’s YolTech, uses in vivo base editing to target the SERPINA1 E342K mutation in alpha‑1 antitrypsin deficiency, reflecting growing cross‑Pacific biotech collaborations.